In clinical trials, tezepelumab, an anti-TSLP monoclonal antibody, demonstrated good safety and tolerability profiles, with linear pharmacokinetics in both healthy individuals and AD subjects (45). This evidence concerns the gene TSLP and Alzheimer disease.